General News

General News | Jan. 13, 2016

National Institutes of Health Releases Plan to Expedite Lupus Treatments and Cures

The research plan identifies and examines opportunities to increase scientific understanding of lupus, which will ultimately lead to safer and more effective treatments and, eventually, curative strategies

General News | Oct. 29, 2015

First-ever National Lupus Public Health Agenda Provides Roadmap to Improving Care and Treatment

The Agenda for Lupus identifies public health priorities, strategies and recommendations for efforts in lupus biomedical research and clinical care.

General News | Oct. 28, 2015

LFA Awarded Multi-million Dollar Grant to Build Lupus Awareness and Improve Quality of Life

Grant provides an unprecedented opportunity to further build out meaningful programs and services for people with lupus and physicians.

General News | Oct. 01, 2015

Five New Research Studies Funded to Improve Quality of Life for People with Lupus

The Lupus Foundation of America research grants will support important studies on immune cells, pediatric lupus, stem cells, biomarkers, and environmental triggers of lupus.

General News | Sep. 18, 2015

Lupus Highlighted in New Congressional Report on Health Disparities

A new Congressional report includes an article contributed by the Lupus Foundation of America on health disparities among people with lupus and current efforts to improve treatment and diagnosis in minority communities.

General News | Jul. 15, 2015

Lupus Foundation of America’s Collaboration in PARTNERS Seeks to Improve Pediatric Research and Care

Learn more about PARTNERS (Patients, Advocates and Rheumatology Teams Network for Research and Service), a new initiative.

General News | Nov. 15, 2014

Lupus Research Studies Widen Understanding

Foundation-funded research studies highlighted at premier rheumatology meeting in Boston.

General News | Oct. 02, 2014

Foundation Responds to Eli Lilly and Company’s Release of Data from Clinical Trial of Tabalumab

Sandra C. Raymond, President & CEO of the Lupus Foundation of America, issued the following statement in response to Eli Lilly and Company’s announcement of the results of two Phase III clinical trials of tabalumab.